Business Wire · VIR · November 5, 2026

Vir Biotechnology to Present Topline Phase 3 ECLIPSE 1 Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta at AASLD's The Liver Meeting® 2026 and Host Investor Conference Call

Get the app for more

Explore stock news, insights and company research.